Zai Lab Limited (ZLAB)
NASDAQ: ZLAB · Real-Time Price · USD
20.59
+0.26 (1.28%)
At close: May 15, 2026, 4:00 PM EDT
20.55
-0.04 (-0.19%)
After-hours: May 15, 2026, 5:48 PM EDT
Zai Lab Revenue
Zai Lab had revenue of $99.61M in the quarter ending March 31, 2026, a decrease of -6.46%. This brings the company's revenue in the last twelve months to $453.28M, up 8.36% year-over-year. In the year 2025, Zai Lab had annual revenue of $460.16M with 15.33% growth.
Revenue (ttm)
$453.28M
Revenue Growth
+8.36%
P/S Ratio
5.10
Revenue / Employee
$254,081
Employees
1,784
Market Cap
2.31B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 460.16M | 61.17M | 15.33% |
| Dec 31, 2024 | 398.99M | 132.27M | 49.59% |
| Dec 31, 2023 | 266.72M | 51.68M | 24.03% |
| Dec 31, 2022 | 215.04M | 70.73M | 49.01% |
| Dec 31, 2021 | 144.31M | 95.35M | 194.77% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Ultragenyx Pharmaceutical | 670.00M |
| IDEAYA Biosciences | 225.27M |
| Nektar Therapeutics | 55.63M |
| Ocular Therapeutix | 52.04M |
| Relay Therapeutics | 10.68M |
| Immunome | 4.02M |
ZLAB News
- 6 days ago - Zai Lab (ZLAB) Achieves Fast Track Status for New Cancer Treatment - GuruFocus
- 6 days ago - Zai Lab receives FDA Fast Track Designation for zocilurtatug pelitecan - TheFly
- 6 days ago - Zai Lab Receives U.S. FDA Fast Track Designation for Zocilurtatug Pelitecan (Zoci), a DLL3-Targeting ADC, for Treatment of Extrapulmonary Neuroendocrine Carcinomas (epNECs) - Business Wire
- 9 days ago - Zai Lab price target lowered to $44 from $47 at Citi - TheFly
- 9 days ago - Zai Lab (ZLAB) Highlights Strategic Developments and Future Outlook - GuruFocus
- 10 days ago - Zai Lab Q1 2026 Loss Widens to -$0.05/Share, Revenue Down 6% - AlphaStreet
- 10 days ago - Zai Lab Earnings Call Transcript: Q1 2026 - Transcripts
- 10 days ago - Zai Lab reports Q1 EPS (4c), consensus (53c) - TheFly